Results 21 to 30 of about 15,630 (215)
Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain
Pharmaceuticals, 2021 Incentives contribute to the proper functioning of the broader contracts that regulate the relationships between health systems and professionals.
Félix Lobo, Isabel Río-Álvarez
doaj +1 more source
Knowledge and Perception of Iraqi Pharmacists Towards Biosimilar Medicines
Iraqi Journal of Pharmaceutical Sciences, 2021 Biosimilars are non-innovative copy versions of biologic medicines which are proven to be clinically equivalent to, as effective and as safe as their reference biologics.
Ashwaq J. Mohammed, Dheyaa J. Kadhim
doaj +1 more source
PLoS ONE, 2022 Healthcare systems have reached a critical point regarding the question of whether biosimilar substitution should become common practice. To move the discussion forward, the study objective was to investigate the views of experts from medicines agencies ...
Louise C. Druedahl +6 more
doaj +2 more sources
Scientific Reports, 2022 TNF-alpha inhibitors have revolutionized the therapeutic care in chronic inflammatory diseases. Several biosimilar products were commercialized at their patent expiry, substantially decreasing the cost of treatment.
Hugo Jourdain +3 more
doaj +1 more source
Therapeutische Umschau, 2011 Die Bewertung von Biosimilars stellt eine Herausforderung für alle an der Zulassung und an der Arzneimittelauswahl Beteiligten im Gesundheitswesen dar. Bewertungskriterien sind wie bei allen Arzneimitteln Qualität, Wirksamkeit, Sicherheit/Verträglichkeit und Wirtschaftlichkeit.
openaire +6 more sources
Therapeutic Advances in Gastroenterology, 2023 Background: Many patients with inflammatory bowel disease (IBD) have transitioned from an infliximab originator to a biosimilar. However, some patients retransition to the originator (i.e. stop biosimilar and reinitiate the originator). Whether this sign
Rosanne W. Meijboom +6 more
doaj +1 more source
Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation [PDF]
Терапевтический архив, 2019 Real - life data on the effectiveness and safety of biosimilar and biologic drugs licensed for treatment of inflammatory bowel diseases (IBD) is lacking. Aim.
O V Knyazev +7 more
doaj +1 more source
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
Pharmaceutics, 2020 Biosimilar medicines expand the biotherapeutic market and improve patient access. This work looked into the landscape of the European and US biosimilar products, their regulatory authorization, market availability, and clinical evaluation undergone prior
Ioana Gherghescu +1 more
doaj +1 more source
Rheumatology International, 2014 Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F. +4 more
openaire +2 more sources
Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data [PDF]
, 2017 In 2006, the European Medicines Agency (EMA) approved Omnitrope(®) as a biosimilar recombinant human growth hormone (rhGH), on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin(®), Pfizer).
Zabransky, Markus +11 more
core +1 more source